NCT05836012View on ClinicalTrials.gov

Safety and Immunogenicity of HIL-214 With Routine Pediatric Vaccines

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

329

Participants

Timeline

Start Date

June 10, 2023

Primary Completion Date

January 19, 2024

Study Completion Date

July 8, 2024

Conditions
Gastroenteritis
Interventions
BIOLOGICAL

HIL-214

2 injections - given at 4 months and the second at 6 months of age.

BIOLOGICAL

Placebo

2 injections - given at 4 months and the second at 6 months of age.

Trial Locations (12)

59804

Boeson Research MSO, Missoula

68516

Frontier Pediatric Care, Lincoln

68901

Velocity Clinical Research - Hastings, Hastings

70508

Velocity Clinical Research - Lafayette, Lafayette

77071

La Providence Pediatrics Clinic - Chemidox Clinical Trials (Hypercore), Houston

84037

Alliance for Multispecialty Research LLC - Kaysville, Kaysville

84075

Alliance for Multispecialty Research LLC - Syracuse, Syracuse

Unknown

CEVAXIN-La Chorrera, La Chorrera

Cervaxin-Avenida Mexico, Panama City

Cervaxin-Tocumen, Panama City

00907

BRCR Global, San Juan

00936

HACTR, San Juan

Sponsors

Lead Sponsor

HilleVax
All Listed Sponsors
lead

HilleVax

INDUSTRY

NCT05836012 - Safety and Immunogenicity of HIL-214 With Routine Pediatric Vaccines | Biotech Hunter | Biotech Hunter